Akers Biosciences Responds to Erroneous Earnings Call Press Release
Akers Biosciences, Inc. (NASDAQ: AKER) clarified that a press release regarding an earnings call by Aker ASA was mistakenly issued under its name.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a company wholly unrelated to the Company. The press release was errantly issued by the newswire services under the Company’s name. The Company has not scheduled any earnings calls. The Company is investigating how this error occurred and reserves all rights to pursue all appropriate remedies upon learning more about the cause of this error.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005868/en/